US News

Biogen’s Alzheimer’s drug gets negative vote from European panel

Published by

(Reuters) -Biogen Inc’s marketing application for its Alzheimer’s disease drug was voted down by a European Medicines Agency (EMA) panel, in the latest blow to the U.S. drugmaker, sending its shares down 3% in trading before the bell. The negative vote by the panel will be taken into consideration by the EMA, which is not bound to follow its panel’s recommendation, but usually does. “Given the existing data and controversy attached to the drug, we see no reason why there would be a divergence (in EMA’s decision),” said Wedbush analyst Laura Chico. The drug, Aduhelm, was approved by U.S. regula…

Read More

Facebook Comments

Check Also

Germany plans to make vaccination compulsory for some jobs – draft

Published by Reuters BERLIN (Reuters) – The incoming ...